Insulin lispro is an insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. It is available as injection and injectable suspension for subcutaneous and intravenous use. MedsAcross supplies Insulin lispro for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Source: US FDA prescribing information
Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
Source: US FDA prescribing information
See Full Prescribing Information for important preparation and administration instructions. Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. Subcutaneous injection: Administer ADMELOG by subcutaneous injection into the abdominal wall, thigh, upper arm, or buttocks within 15 minutes before a meal or immediately after a meal. Continuous subcutaneous infusion (Insulin Pump): Refer to the insulin infusion pump user manual to see if ADMELOG can be used. Use in accordance with the insulin pump instructions for use. Administer ADMELOG by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. Rotate infusion sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. Do not mix with other insulins or diluents in the pump.
Source: US FDA prescribing information
ADMELOG is contraindicated: during episodes of hypoglycemia. in patients who are hypersensitive to insulin lispro or to any of the excipients in ADMELOG. Do not use during episodes of hypoglycemia. Do not use in patients with hypersensitivity to insulin lispro or any of the excipients in ADMELOG.
Source: US FDA prescribing information
Never share an ADMELOG SoloStar disposable prefilled pen or syringe between patients, even if the needle is changed. Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Make changes to a patient's insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring. Hypoglycemia: May be life-threatening. Monitor blood glucose and increase monitoring frequency with changes to insulin dosage, use of glucose lowering medications, meal pattern, physical activity, in patients with renal or hepatic impairment, and in patients with hypoglycemia unawareness. Hypoglycemia Due to Medication Errors: Accidental mix-ups between insulin products can occur. Instruct patients to check insulin labels before injection. Hypersensitivity Reactions: May be life-threatening.
Source: US FDA prescribing information
The following adverse reactions are discussed elsewhere: Hypoglycemia Hypoglycemia Due to Medication Errors Hypersensitivity Reactions Hypokalemia Adverse reactions associated with ADMELOG include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash.
Source: US FDA prescribing information
Table 2 presents clinically significant drug interactions with ADMELOG. Table 2: Clinically Significant Drug Interactions with ADMELOG Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs.
Source: US FDA prescribing information
Do not freeze and do not use ADMELOG if it has been frozen. ADMELOG Not In-Use (Unopened) Room Temperature (Up to 86°F [30°C]) Not In-Use (Unopened) Refrigerated (36°F–46°F [2°C–8°C]) In-Use (Opened) Room Temperature (Up to 86°F [30°C]) 10 mL multiple-dose vial 28 days Until expiration date 28 days refrigerated/room temperature 3 mL multiple-dose vial 28 days Until expiration date 28 days refrigerated/room temperature 3 mL single-patient-use SoloStar prefilled pen 28 days Until expiration date 28 days Do not refrigerate.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
20 presentations of Insulin lispro, sorted by availability.
15 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Insulin lispro in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 20 presentations of Insulin lispro and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 15 brand names for Insulin lispro, including Admelog, Humalog, Humalog Junior KwikPen, Humalog KwikPen, Humalog Mix50/50 KwikPen, Humalog Mix75/25, Humalog Mix75/25 KwikPen, Humalog Tempo Pen.
Yes. The US FDA first approved Insulin lispro on 11 December 2017, according to Drugs@FDA.
Yes. Insulin lispro has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Insulin lispro must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Insulin lispro is classified under ATC code A10AB04 (Insulin lispro).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.